

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

LOAN FACILITY WITH CHINA DEVELOPMENT BANK - ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES

The Board announces that the Company as borrower entered into a facility agreement with China Development Bank Corporation Hong Kong Branch for a HK\$600,000,000 unsecured term-loan facility. The principal amount under the Facility shall be repaid in full after the expiry of a 36 months term from the relevant utilisation date.

Pursuant to the Agreement, if there occurs a change of control of the Company, the Lender may (i) cancel the commitment under the Facility, and (ii) declare all outstanding loans under the Facility, together with accrued interest and all other amounts accrued under the finance documents, to be immediately due and payable.

This announcement is made pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors (the “**Board**”) of the Company announces that, as an existing three-year term loan facility with China Development Bank Corporation Hong Kong Branch (the “**Lender**”) will expire in June 2016, the Company as borrower entered into a facility agreement (the “**Agreement**”) with the Lender for a HK\$600,000,000 unsecured term-loan facility (the “**Facility**”) upon the expiry of the existing loan facility. The principal amount under the Facility shall be repaid in full after the expiry of a 36 months term from the relevant utilisation date.

Pursuant to the Agreement, if there occurs a change of control of the Company, the Lender may (i) cancel the commitment under the Facility, and (ii) declare all outstanding loans under the Facility, together with accrued interest and all other amounts accrued under the finance documents, to be immediately due and payable. Pursuant to the Agreement, (i) a “change of control” occurs if any person or group of persons acting in concert (as defined under the Hong Kong Codes of Takeovers and Merger and Share Repurchases), other than the person or group of persons who currently have control, gains control of the Company; and (ii) “control” means the power to exercise or control the exercise of 50 per cent. or more of the voting power at general meetings of the Company, or to control the composition of the majority of the Board, whether through the ownership of voting capital, by contract or otherwise.

As at the date of this announcement, Nautilus Trustees Asia Limited (formerly known as DBS Trustee H.K. (Jersey) Limited) (as the trustee of The Choy Family Trust), through its wholly-owned subsidiaries, Gesell Holdings Limited and Heren Far East Limited, Ms. Ning Kwai Chun, Mr. Tsoi Hoi Shan and Ms. Choy Siu Chit (all being members of the Choy family), are collectively holding 1,075,157,000 shares of the Company, representing approximately 66.09% of the issued share capital of the Company.

The Company will continue to comply with the disclosure obligations under Rule 13.21 of the Listing Rules for so long as circumstance giving rise to the above obligation continue to exist.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Tsoi Hoi Shan
Chairman

Hong Kong, 28 June 2016

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.